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Conventional adenomas have historically been considered to be the only screening-relevant colorectal cancer (CRC) precursor 
lesion. The prevailing paradigm was that most CRCs arise along the chromosomal instability pathway, where adenomas accumulate 
incremental genetic alterations over time, leading eventually to malignancy. However, it is now recognized that this “conventional” 
pathway accounts for only about two-thirds of CRCs. The serrated pathway is responsible for most of the remainder, and is a 
disproportionate contributor to postcolonoscopy CRC. Hallmarks of the serrated pathway are mutations in the BRAF gene, high levels 
of methylation of promoter CpG islands, and the sessile serrated polyp (SSP). Accumulating evidence shows that SSPs can be considered 
adenoma-equivalent from the standpoint of CRC screening. SSPs have a higher prevalence than previously thought, and appear to 
have a relatively long dwell time similar to that of conventional adenomas. In addition, SSPs, whether sporadic or as part of the serrated 
polyposis syndrome, are associated with increased risk of synchronous and metachronous neoplasia. These features collectively support 
that SSPs are highly relevant to CRC prevention. Clin Endosc  2019;52:235-238
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INTRODUCTION
Colorectal cancer (CRC) is amenable to primary prevention, 
which means that incidence and mortality can be reduced 
via screening and removal of precursor lesions before cancer 
occurs. Successful CRC screening fundamentally depends on 
the ability to detect and resect precursor lesions with relatively 
long dwell time. This paradigm has long been established for 
conventional adenomas, but the more recent emergence of 
serrated lesions in the CRC field has led to questions about its 
applicability to sessile serrated polyp (SSP). There are present-
ly no prospective studies showing a measurable independent 
impact of SSP removal on CRC outcomes. This may be largely 
due to the relatively recent recognition of the importance of 
SSP in the CRC prevention field, compared to the very ex-
tensively studied conventional adenomas. Nevertheless, an 
extensive and growing literature provides several converging 
lines of evidence suggesting that SSP have a central role in 
CRC prevention. Recent studies describe the distinct biologic 
features of the serrated pathway to colorectal neoplasia, and 
reveal that SSP have high prevalence, a relatively long dwell 
time, and are associated with increased risk of both synchro-
nous and metachronous colorectal neoplasia. A review of this 
literature is presented in the following sections.
The SeRRaTeD PaThway
Serrated polyps are distinct from conventional adenomas 
and are characterized histologically by a saw-tooth appear-
ance of the crypt epithelium.1 This class of lesions includes 
hyperplastic polyps, SSP, and traditional serrated adenomas 
(TSA). SSP and TSA are both considered premalignant le-
sions; however, TSA are very rare lesions and are less well-un-
derstood than SSP. Distortion of crypt growth pattern leading 
to abnormal-appearing crypt bases is characteristic of SSP. 
An activating mutation of the BRAF oncogene appears to 
be a fundamental step in the SSP-to-CRC serrated neoplasia 
pathway, and a characteristic feature is abnormal hypermeth-
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ylation of CpG islands in gene promoter regions, termed CpG 
island-methylator phenotype (CIMP). This hypermethylation 
can be extensive and lead to epigenetic silencing of genes, 
such as the mutation mismatch repair gene MLH1 (also im-
plicated in Lynch syndrome). This event leads to acceleration 
of development of cytological dysplasia (via the intermediate 
SSP with cytological dysplasia), and progression to CRC with 
microsatellite instability (MSI). Most CRCs with MSI and 
CIMP molecular signatures originate from the serrated path-
way, with the SSP as the main precursor lesion.2
Additional evidence supporting the existence of a separate 
serrated pathway to CRC includes the observation that SSP 
may have risk factors distinct from those typically associated 
with adenomas. For example, calcium and vitamin D sup-
plementation are associated with increased risk of SSP,3 while 
obesity, folate intake, fiber and fat intake are not.4
NaTURal hISTORy OF SSP
The natural history of SSP and rate of progression to CRC 
are not as clear compared to conventional adenomas and the 
adenoma-carcinoma sequence. However, the available evi-
dence suggests comparable progression rates, with SSPs gener-
ally following an indolent or slowly progressive course, until a 
critical event (notably, MLH1 silencing) which accelerates the 
progression to dysplasia and cancer.
A pathological series5 of 2,319 patients with 2,416 SSPs 
reported that the median age of patients increased as the his-
tologic grade of the lesion worsened, from 61 years for SSP 
without dysplasia, to 76 years for CRC. A recent cross-sec-
tional analysis6 of 137 SSPs with dysplasia or cancer showed 
that older age, female gender, proximal location, CIMP, and 
lack of aberrant p53 were all associated with loss of MLH1 
expression. The age of patients with dysplastic SSP was similar 
to those with cancer (about 76 years), and together, 17 years 
older than a historical cohort of patients with SSP without 
dysplasia.
Collectively, these data show that SSP without dysplasia 
generally have a long dwell time of at least 15 years, similar 
to conventional adenomas. This is a critically important ob-
servation, because uniformly rapid progression of serrated 
neoplasms would have threatened current CRC prevention 
paradigms which rely on relatively long latency of CRC and 
its precursor lesions.
PRevaleNCe
Until recently, there has been uncertainty regarding the true 
prevalence of SSP. Older studies addressing this question were 
limited because they reported aggregate data for endoscopists 
with wide ranges in individual detection rates, and because 
there is significant inter-observer variability among pathol-
ogists in the differentiation of serrated lesion subtypes. The 
true prevalence of SSP is important to define, because a rare 
lesion would not be a reasonable target to screen for. Recent 
colonoscopy studies7,8 involving endoscopists with high-level 
detection rates reported SSP prevalence of 8% to 9% (0.4% to 
0.6% for SSP with cytological dysplasia). These studies show 
that SSP have higher prevalence than previously thought, 
adding further support to their screening relevance.
SeRRaTeD NeOPlaSIa aND 
POSTCOlONOSCOPy CRC
There is significant overlap in the molecular signatures of 
postcolonoscopy CRC (PCCRC) and the serrated pathway. 
Compared to sporadic CRC, PCCRC is more likely to demon-
strate MSI and be associated with CIMP. In addition, PCCRC 
is more likely to be located in the proximal colon,9-11 the area 
of predilection for SSP.
The majority of PCCRC are due to operator-dependent 
factors, and this is reflected in its inverse association with ad-
enoma detection rate (ADR). The issues surrounding variable 
adenoma detection and its impact on the effectiveness of colo-
noscopy may also apply to serrated polyps, although there is 
currently no evidence that the variability in proximal serrated 
polyp detection is independently associated with PCCRC risk. 
Several studies have shown that the variability in detection of 
proximal serrated polyps exceeds that of adenomas among 
the same groups of endoscopists, and can range up to 18- fold 
(compared to 3- to 4- fold for the ADR).12-14 SSPs have subtle 
morphology which renders them more likely to be overlooked 
by operators not familiar with their endoscopic characteris-
tics. Longer withdrawal time is significantly associated with 
improved proximal serrated polyp detection. An analysis15 
of nearly 8,000 colonoscopies in the New Hampshire Colo-
noscopy Registry found that the detection of serrated polyps 
proximal to the sigmoid colon increased with each minute 
of withdrawal time above 6 minutes. Studies have generally 
shown a strong correlation between adenoma and serrated 
polyp detection,13 which is plausible because endoscopists who 
have meticulous examination technique would be expected to 
be proficient at detecting polyps of all types.
Their endoscopic features also render serrated polyps prone 
to incomplete resection, as shown in the Complete Adenoma 
Resection study.16 However, more recent studies show that ded-
icated endoscopic mucosal resection methods, with submuco-
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sal injection with dye to highlight lesion borders, are associated 
with effective and complete resection of serrated polyps.17,18
aSSOCIaTION wITh SyNChRONOUS 
NeOPlaSIa
Several lines of evidence show that serrated polyps not only 
possess intrinsic risk of progression to CRC, but also alter 
the colorectal milieu in a manner which promotes neoplastic 
processes. A systematic review and meta-analysis19 of 9 studies 
with 34,000 subjects reported that individuals with serrated 
polyps had a 2-fold increased odds of advanced neoplasia; 
proximal location and large size were associated with even 
higher odds. The most extreme manifestation of serrated 
neoplasia is the serrated polyposis syndrome (SPS), which is 
defined as the presence of at least 5 serrated polyps proximal 
to the sigmoid colon with 2 or more measuring at least 10 
mm in diameter, any number of serrated polyps proximal to 
the sigmoid colon in a person with a first-degree relative with 
SPS, or >20 serrated polyps of any size distributed throughout 
the colon.1 SPS is the most common polyposis syndrome, with 
reported prevalence rates ranging from 1 in 238 to 1 in 111 in 
colonoscopy and fecal test-based screening programs, respec-
tively20,21 SPS is associated with increased risk of CRC, war-
ranting close endoscopic surveillance of patients with SPS.22 
Recent reports,23 however, suggest that the risk of CRC in SPS 
is highest at the time of diagnosis: in a Spanish study of 296 
SPS patients, CRC was found in 47 patients at mean age of 54 
years, and only 4 cases were detected during surveillance (5-
year incidence of 1.9%).
aSSOCIaTION wITh MeTaChRONOUS 
NeOPlaSIa
Convincing evidence shows that SSP are associated with 
risk of metachronous neoplasia. A recent study24 reported the 
long-term follow-up of 13,000 individuals in the Norwegian 
flexible sigmoidoscopy screening trial (NORCCAP), where 
patients with serrated polyps were re-invited for colonoscopy 
over a decade after initial enrollment. Compared with controls 
without polyps, the hazard ratio for CRC was 2.5 for patients 
with large serrated polyps, comparable to those who had an 
advanced adenoma (2.0). Interestingly, there were 23 large ser-
rated polyps found at screening were left in situ for a median 
of 11 years, and none had progressed to CRC; this observation 
is further evidence that SSP exert a pro-neoplastic influence 
on the colorectal milieu, independent of their intrinsic risk of 
progression. A large population-based study25 from Denmark 
assessed the risk of CRC associated with SSP. Among 272,342 
individuals who had received colonoscopy between 1977 and 
2009, there were 2,045 CRC cases and 8,105 age- and sex-
matched controls without CRC. The investigators identified 
the first colorectal polyp(s) that had been resected or biopsied 
on the initial or subsequent colo noscopy, and polyps that 
were initially interpreted as hyperplas tic were re-reviewed by 
expert pathologists. Patients with SSP are at increased risk for 
CRC, to a degree at least equivalent to that of patients with 
conventional adenomas (Table 1).25
A recently published analysis26 of the New Hampshire 
population-based colonoscopy registry showed that patients 
with large serrated polyps or SSP at baseline had higher risk 
of large serrated polyps at follow-up (odds ratio, 9.7 to 14.3), 
whereas patients with high-risk adenoma (HRA) plus SSP had 
risk of metachronous HRA which was 4 times higher than 
those with baseline HRA alone.
CONClUSIONS
SSPs contribute significantly to the burden of CRC, and 
recognition of their importance has direct implications for 
CRC screening paradigms. The existence of a distinct biologic 
Table 1. Odds of Colorectal Cancer according to Baseline Polyp Type25
adjusted OR (95% CI) estimated 10-year risk
SSP with synchronous conventional adenomas 2.66 (1.70–4.16) 2.47%
SSP without synchronous conventional adenomas 3.40 (2.35–4.91) 3.16%
SSP with cytologic dysplasia 4.76 (2.59–8.73) 4.43%
SSP without cytologic dysplasia 2.75 (1.99–3.80) 2.56%
Conventional adenomas without SSP 2.50 (2.24–2.80) 2.33%
TSA overall 4.84 (2.36–9.93) 4.50%
Hyperplastic polyps only 1.30 (0.96–1.77) 1.21%
CI, confidence interval; OR, odds ratio; SSP, sessile serrated polyp; TSA, traditional serrated adenomas.
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pathway, high prevalence, relatively long dwell time, relation 
to PCCRC, and association with synchronous and metachro-
nous neoplasia render SSPs highly screening-relevant. Contin-
ued efforts to ensure that endoscopists achieve high levels of 
detection and complete resection are critical for effective CRC 
prevention at colonoscopy.
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